Trial Profile
Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Cord blood stem cell therapy (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Gamida-Cell
- 10 Sep 2013 New trial record
- 06 Aug 2013 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.